← Back to Screener
Entrada Therapeutics, Inc. Common Stock (TRDA)
Price$13.99
Favorite Metrics
Price vs S&P 500 (26W)120.97%
Price vs S&P 500 (4W)14.20%
Market Capitalization$535.60M
P/E Ratio (Annual)7.40x
All Metrics
Book Value / Share (Quarterly)$8.00
P/TBV (Annual)1.80x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.38
Price vs S&P 500 (YTD)31.95%
Net Profit Margin (TTM)-565.48%
EPS (TTM)$-3.47
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-3.47
EPS (Annual)$-3.47
ROI (Annual)-46.96%
Cash / Share (Quarterly)$7.72
Revenue Growth QoQ (YoY)-96.53%
P/E Normalized (Annual)7.40x
ROA (Last FY)-38.09%
Revenue Growth TTM (YoY)-87.94%
EBITD / Share (TTM)$-3.72
ROE (5Y Avg)-19.21%
Operating Margin (TTM)-621.13%
Cash Flow / Share (Annual)$-3.38
P/B Ratio1.75x
P/B Ratio (Quarterly)1.28x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)17.51x
Net Interest Coverage (TTM)-1704.33x
ROA (TTM)-33.32%
EV / EBITDA (TTM)55.71x
EPS Incl Extra (Annual)$-3.47
Current Ratio (Annual)12.53x
Quick Ratio (Quarterly)12.17x
3-Month Avg Trading Volume0.21M
52-Week Price Return77.99%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.40
P/S Ratio (Annual)21.07x
Asset Turnover (Annual)0.07x
52-Week High$14.49
EPS Excl Extra (Annual)$-3.47
CapEx CAGR (5Y)-14.88%
26-Week Price Return129.72%
Quick Ratio (Annual)12.17x
13-Week Price Return32.23%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.53x
Enterprise Value$445.204
Asset Turnover (TTM)0.06x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-561.84%
Cash / Share (Annual)$7.72
3-Month Return Std Dev59.56%
Net Income / Employee (TTM)$-1
ROE (Last FY)-46.96%
EPS Basic Excl Extra (Annual)$-3.47
P/FCF (TTM)3.45x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.47
ROI (TTM)-39.83%
P/S Ratio (TTM)21.07x
Revenue / Share (Annual)$0.61
Tangible BV / Share (Annual)$6.77
Price vs S&P 500 (52W)42.89%
Year-to-Date Return36.09%
5-Day Price Return0.72%
EPS Normalized (Annual)$-3.47
ROA (5Y Avg)-16.26%
Net Profit Margin (Annual)-565.48%
Month-to-Date Return10.86%
Cash Flow / Share (TTM)$-0.58
EBITD / Share (Annual)$-3.72
Operating Margin (Annual)-621.13%
ROI (5Y Avg)-19.21%
EPS Basic Excl Extra (TTM)$-3.47
P/TBV (Quarterly)1.55x
P/B Ratio (Annual)1.28x
Pretax Margin (TTM)-561.84%
Book Value / Share (Annual)$8.00
Price vs S&P 500 (13W)29.37%
Beta-0.08x
P/FCF (Annual)3.99x
Revenue / Share (TTM)$0.61
ROE (TTM)-39.83%
52-Week Low$4.93
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.18
4.25
4.31
4.31
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TRDAEntrada Therapeutics, Inc. Common Stock | 21.07x | -87.94% | — | — | $13.99 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing medicines to treat neuromuscular and ocular diseases using its proprietary Endosomal Escape Vehicle (EEV) platform, which enables efficient delivery of therapeutic molecules into cells. The company's pipeline focuses on oligonucleotide therapies for Duchenne muscular dystrophy through multiple exon-skipping approaches, and includes a partnered program for myotonic dystrophy type 1. By targeting previously inaccessible intracellular sites, Entrada aims to improve therapeutic efficacy for serious genetic diseases.